Michael Weller

164.6k total citations · 33 hit papers
1.2k papers, 89.1k citations indexed

About

Michael Weller is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Weller has authored 1.2k papers receiving a total of 89.1k indexed citations (citations by other indexed papers that have themselves been cited), including 578 papers in Genetics, 384 papers in Molecular Biology and 265 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Weller's work include Glioma Diagnosis and Treatment (568 papers), Brain Metastases and Treatment (207 papers) and Cell death mechanisms and regulation (91 papers). Michael Weller is often cited by papers focused on Glioma Diagnosis and Treatment (568 papers), Brain Metastases and Treatment (207 papers) and Cell death mechanisms and regulation (91 papers). Michael Weller collaborates with scholars based in Germany, Switzerland and United States. Michael Weller's co-authors include Wolfgang Wick, Roger Stupp, Martin J. van den Bent, Thierry Gorlia, Warren Mason, R.O. Mirimanoff, J. Gregory Cairncross, Robert C. Janzer, Guido Reifenberger and Alba A. Brandes and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Michael Weller

1.2k papers receiving 87.6k citations

Hit Papers

Radiotherapy plus Concomi... 2002 2026 2010 2018 2005 2005 2011 2018 2020 5.0k 10.0k 15.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
    2005 16.0k citations Roger Stupp, Warren Mason et al. profile →
  2. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
    2005 5.2k citations Monika E. Hegi, Thierry Gorlia et al. profile →
  3. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
    2011 1.4k citations Felix Sahm, Michael Weller et al. profile →
  4. Current state of immunotherapy for glioblastoma
    2018 951 citations Michael Weller et al. profile →
  5. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
    2020 946 citations Patrick Roth, Michael Weller et al. profile →
  6. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
    2009 868 citations Christian Hartmann, Jörg Felsberg et al. profile →
  7. Glioma
    2015 792 citations Michael Weller, Wolfgang Wick et al. profile →
  8. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
    2012 769 citations Wolfgang Wick, Michael Platten et al. profile →
  9. Long-term survival with glioblastoma multiforme
    2007 676 citations Dietmar Krex, Christian Hartmann et al. profile →
  10. Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
    2008 658 citations Monika E. Hegi, Roger Stupp et al. Journal of Clinical Oncology profile →
  11. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
    2010 627 citations Christian Hartmann, Bettina Hentschel et al. profile →
  12. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
    2002 605 citations Wolfgang Wick, Michael Weller et al. profile →
  13. Standards of care for treatment of recurrent glioblastoma—are we there yet?
    2012 587 citations Michael Weller, Wolfgang Wick et al. Neuro-Oncology profile →
  14. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
    2009 575 citations Michael Weller, Roger Stupp et al. profile →
  15. NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
    2009 571 citations Wolfgang Wick, Christian Hartmann et al. Journal of Clinical Oncology profile →
  16. EANO guidelines for the diagnosis and treatment of meningiomas
    2016 571 citations Roland Goldbrunner, Matthias Preusser et al. profile →
  17. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
    2014 568 citations Michael Weller, Martin J. van den Bent et al. profile →
  18. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”
    2018 553 citations Guido Reifenberger, Roger Stupp et al. profile →
  19. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
    2016 490 citations Nathalie L. Albert, Michael Weller et al. Neuro-Oncology profile →
  20. Advances in the molecular genetics of gliomas — implications for classification and therapy
    2016 486 citations Guido Reifenberger, Hans‐Georg Wirsching et al. profile →
  21. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
    2015 471 citations Michael Weller, Mark R. Gilbert et al. profile →
  22. Molecular targeted therapy of glioblastoma
    2019 466 citations Émilie Le Rhun, Matthias Preusser et al. profile →
  23. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
    2014 445 citations Michael Weller, Monika E. Hegi et al. Neuro-Oncology profile →
  24. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
    2017 426 citations Émilie Le Rhun, Michael Weller et al. profile →
  25. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes
    2020 417 citations Michael Weller et al. profile →
  26. MGMT testing—the challenges for biomarker-based glioma treatment
    2014 393 citations Wolfgang Wick, Michael Weller et al. profile →
  27. EANO guideline on the diagnosis and management of meningiomas
    2021 350 citations Roland Goldbrunner, Felix Sahm et al. Neuro-Oncology profile →
  28. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0
    2018 341 citations Nathalie L. Albert, Michael Weller et al. profile →
  29. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
    2016 339 citations Matthias Preusser, Émilie Le Rhun et al. Neuro-Oncology profile →
  30. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
    2020 310 citations Guido Reifenberger, Roger Stupp et al. profile →
  31. EANO guideline on the diagnosis and treatment of vestibular schwannoma
    2019 230 citations Roland Goldbrunner, Michael Weller et al. Neuro-Oncology profile →
  32. Glioma
    2024 173 citations Michael Weller, Guido Reifenberger et al. profile →
  33. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma
    2023 90 citations Martin J. van den Bent, Michael Weller et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael Weller 43.6k 33.2k 17.1k 17.0k 16.5k 1.2k 89.1k
David N. Louis 37.3k 0.9× 27.9k 0.8× 17.5k 1.0× 17.0k 1.0× 15.3k 0.9× 322 75.2k
Andreas von Deimling 31.1k 0.7× 22.7k 0.7× 10.4k 0.6× 13.1k 0.8× 9.1k 0.6× 652 59.5k
Webster K. Cavenee 22.4k 0.5× 31.7k 1.0× 8.8k 0.5× 13.7k 0.8× 12.7k 0.8× 315 62.0k
Roger Stupp 31.2k 0.7× 15.7k 0.5× 13.9k 0.8× 10.7k 0.6× 9.5k 0.6× 376 49.8k
Martin J. van den Bent 35.2k 0.8× 12.7k 0.4× 14.9k 0.9× 9.9k 0.6× 8.1k 0.5× 579 51.0k
Guido Reifenberger 29.1k 0.7× 18.3k 0.6× 8.9k 0.5× 12.3k 0.7× 5.8k 0.4× 354 47.6k
Paul Kleihues 27.6k 0.6× 19.8k 0.6× 8.5k 0.5× 11.7k 0.7× 7.8k 0.5× 296 53.7k
Patrick Y. Wen 23.9k 0.5× 12.3k 0.4× 11.6k 0.7× 8.0k 0.5× 9.9k 0.6× 781 43.2k
Darell D. Bigner 18.5k 0.4× 22.1k 0.7× 6.5k 0.4× 10.4k 0.6× 15.6k 0.9× 623 48.1k
Henry S. Friedman 21.5k 0.5× 15.0k 0.5× 7.9k 0.5× 7.5k 0.4× 9.0k 0.5× 567 38.4k

Countries citing papers authored by Michael Weller

Since Specialization
Citations

This map shows the geographic impact of Michael Weller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Weller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Weller more than expected).

Fields of papers citing papers by Michael Weller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Weller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Weller. The network helps show where Michael Weller may publish in the future.

Co-authorship network of co-authors of Michael Weller

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Weller. A scholar is included among the top collaborators of Michael Weller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Weller. Michael Weller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albert, Nathalie L., Émeline Tabouret, Émilie Le Rhun, et al.. (2025). TIP-01. [177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial. Neuro-Oncology. 27(Supplement_5). v419–v420.
2.
Wirsching, Hans‐Georg & Michael Weller. (2023). Immunotherapy for Meningiomas. Advances in experimental medicine and biology. 1416. 225–234. 3 indexed citations
3.
Silginer, Manuela, et al.. (2020). Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation. Molecular Cancer Therapeutics. 19(6). 1328–1339. 23 indexed citations
4.
Wirsching, Hans‐Georg, Ulrich Roelcke, Jonathan Weller, et al.. (2020). MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clinical Cancer Research. 27(1). 179–188. 23 indexed citations
5.
Silginer, Manuela, Michael Weller, Hannah Schneider, et al.. (2019). Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas. Clinical Cancer Research. 25(23). 7189–7201. 39 indexed citations
6.
Hegi, Monika E., Thierry Gorlia, Roger Stupp, et al.. (2018). MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research. 25(6). 1809–1816. 90 indexed citations
7.
Weiß, Tobias, Hannah Schneider, Manuela Silginer, et al.. (2017). NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Clinical Cancer Research. 24(4). 882–895. 90 indexed citations
8.
Weiß, Tobias, Michael Weller, Matthias Gückenberger, Charles L. Sentman, & Patrick Roth. (2017). NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Research. 78(4). 1031–1043. 231 indexed citations
9.
Seystahl, Katharina, Isabel Burghardt, Hannah Schneider, et al.. (2017). Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma. Molecular Cancer Therapeutics. 16(6). 1177–1186. 45 indexed citations
10.
Happold, Caroline, Patrick Roth, Manuela Silginer, et al.. (2014). Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. Molecular Cancer Therapeutics. 13(4). 948–961. 43 indexed citations
11.
Wick, Wolfgang, Christoph Meisner, Bettina Hentschel, et al.. (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 81(17). 1515–1522. 173 indexed citations
12.
Hartmann, Christian, Bettina Hentschel, Matthias Simon, et al.. (2013). Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. Clinical Cancer Research. 19(18). 5146–5157. 138 indexed citations
13.
Lemke, Dieter, Felix Sahm, Tore Kempf, et al.. (2011). Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness. Clinical Cancer Research. 18(1). 105–117. 118 indexed citations
14.
Stupp, Roger, Monika E. Hegi, Bart Neyns, et al.. (2010). Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(16). 2712–2718. 341 indexed citations
15.
Wick, Wolfgang, Vinay K. Puduvalli, Marc C. Chamberlain, et al.. (2010). Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology. 28(7). 1168–1174. 359 indexed citations
16.
Roth, Patrick, Maria Kissel, Günter Eisele, et al.. (2009). SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo. Clinical Cancer Research. 15(21). 6609–6618. 15 indexed citations
17.
Wick, Wolfgang, Christian Hartmann, Corinna Engel, et al.. (2009). NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology. 27(35). 5874–5880. 571 indexed citations breakdown →
18.
Weller, Michael, Jörg Felsberg, Christian Hartmann, et al.. (2009). Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology. 27(34). 5743–5750. 476 indexed citations
19.
Wiendl, Heinz, et al.. (2003). March 2003: A 41‐year‐old female with a solitary lesion in the liver. Brain Pathology. 13(3). 421–422. 12 indexed citations
20.
Platten, Michael, Wolfgang Wick, & Michael Weller. (2001). Malignant glioma biology: Role for TGF-? in growth, motility, angiogenesis, and immune escape. Microscopy Research and Technique. 52(4). 401–410. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David N. Louis Breakdown of academic impact, for papers by Andreas von Deimling Breakdown of academic impact, for papers by Webster K. Cavenee Breakdown of academic impact, for papers by Roger Stupp Breakdown of academic impact, for papers by Martin J. van den Bent Breakdown of academic impact, for papers by Guido Reifenberger Breakdown of academic impact, for papers by Paul Kleihues Breakdown of academic impact, for papers by Patrick Y. Wen Breakdown of academic impact, for papers by Darell D. Bigner Breakdown of academic impact, for papers by Henry S. Friedman
Rankless by CCL
2026